title: Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
authors.affiliation: Pathology Service, Addarii Institute of Oncology, Bologna, Italy.
authors.forename: Michelangelo
authors.initials: M
authors.lastname: Fiorentino
authors.forename: Francesca
authors.initials: F
authors.lastname: Giunchi
authors.forename: Annalisa
authors.initials: A
authors.lastname: Altimari
authors.forename: Piergiorgio
authors.initials: P
authors.lastname: Di Tullio
authors.forename: Elisa
authors.initials: E
authors.lastname: Gruppioni
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Martorana
authors.forename: Carmine
authors.initials: C
authors.lastname: Pinto
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D019459:Urothelium / Q000473:pathology; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D003841:Deoxycytidine; D016190:Carboplatin; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib; D000093542:Gemcitabine